Capital Group Investment Management PTE. LTD. Reduces Position in Amgen Inc. $AMGN

Key Points

• Capital Group Investment Management PTE. LTD. reduced its Amgen stake by 50.7% in the fourth quarter, leaving it with 5,789 shares valued at about $1.9 million.
• Amgen reported better-than-expected quarterly results, posting EPS of $5.15 versus $4.77 expected and revenue of $8.62 billion, up 5.8% year over year.
• The company also has positive pipeline momentum, including European Commission approval for IMDYLLTRA and encouraging autoimmune data for UPLIZNA and TAVNEOS, while analysts currently rate the stock a consensus Hold with a $353.81 target price.

Capital Group Investment Management PTE. LTD. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 50.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,789 shares of the medical research company's stock after selling 5,943 shares during the quarter. Capital Group Investment Management PTE. LTD.'s holdings in Amgen were worth $1,895,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. lifted its position in Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company's stock valued at $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new position in Amgen during the fourth quarter valued at $1,669,000. Adell Harriman & Carpenter Inc. raised its position in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after acquiring an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Amgen during the 4th quarter worth about $22,441,000. Finally, Kinsale Capital Group Inc. boosted its stake in shares of Amgen by 9.5% during the 3rd quarter. Kinsale Capital Group Inc. now owns 34,193 shares of the medical research company's stock worth $9,649,000 after acquiring an additional 2,959 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 1.2%

AMGN opened at $349.58 on Friday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a 50-day moving average price of $341.35 and a 200 day moving average price of $345.47. The company has a market cap of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.51 and a beta of 0.42.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Truist Financial increased their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a "hold" rating in a research note on Friday, May 1st. Wells Fargo & Company increased their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. Canaccord Genuity Group assumed coverage on shares of Amgen in a research note on Monday, April 20th. They set a "hold" rating and a $366.00 target price on the stock. Piper Sandler lowered their target price on shares of Amgen from $432.00 to $427.00 and set an "overweight" rating on the stock in a research note on Thursday, May 14th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $353.81.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.